Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17681988 | 1.00 | P2RX7 (0.35) | P2RX7GAAMKNK1MKNK2 | |
| SCHEMBL8020852 | 0.81 | TSHR (0.39) | — | |
| SCHEMBL11072786 | 0.78 | P2RX7 (0.40) | P2RX7GAAMKNK1MKNK2 | |
| SCHEMBL22031546 | 0.78 | NAPRT (0.39) | — | |
| SCHEMBL17679295 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL17679296 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL24113945 | 0.76 | P2RX7 (0.39) | P2RX7GAAMKNK1MKNK2 | |
| SCHEMBL5698980 | 0.76 | P2RX7 (0.39) | P2RX7GAAMKNK1MKNK2 | |
| SCHEMBL23489779 | 0.76 | P2RX7 (0.39) | P2RX7GAAMKNK1MKNK2 | |
| SCHEMBL15927758 | 0.76 | P2RX7 (0.39) | P2RX7GAAMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102073-A1 | 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102073-A1 | 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR2 | P2RX7 332/4885GAA 2254/4885MKNK1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.